You think that's already priced into the stock's $1B+ market cap though? Also, looks like this is their only drug so you probably need to have the utmost of confidence the drug will sail through the FDA and be a blockbuster on the market to be invested here.
In these trials, statistically significant improvements in abdominal and bowel symptoms were achieved for linaclotide-treated patients versus placebo-treated patients for all primary and secondary endpoints.
I think efficacy against abdominal pain is the big issue that was not specifically named in the part you've posted.